Medtronic PLC $MDT Shares Sold by Clarkston Capital Partners LLC

Clarkston Capital Partners LLC decreased its position in shares of Medtronic PLC (NYSE:MDT) by 20.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 217,197 shares of the medical technology company’s stock after selling 56,491 shares during the period. Clarkston Capital Partners LLC’s holdings in Medtronic were worth $18,933,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. AXQ Capital LP boosted its position in shares of Medtronic by 25.6% in the second quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after buying an additional 2,013 shares during the period. Legacy Advisory Services LLC acquired a new position in Medtronic during the 1st quarter worth approximately $541,000. GC Wealth Management RIA LLC lifted its position in Medtronic by 20.6% during the 2nd quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock worth $2,926,000 after acquiring an additional 5,734 shares in the last quarter. Verdence Capital Advisors LLC boosted its holdings in Medtronic by 22.0% in the 2nd quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock worth $2,562,000 after acquiring an additional 5,296 shares during the period. Finally, World Investment Advisors grew its position in Medtronic by 1.9% in the second quarter. World Investment Advisors now owns 156,107 shares of the medical technology company’s stock valued at $13,608,000 after acquiring an additional 2,868 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.26% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on MDT. Argus raised their price target on shares of Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, August 26th. Morgan Stanley upped their price objective on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. JPMorgan Chase & Co. lifted their target price on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Royal Bank Of Canada increased their price target on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. Finally, Piper Sandler restated a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $109.72.

Medtronic Stock Performance

Shares of MDT stock opened at $105.13 on Friday. The company has a market cap of $134.85 billion, a P/E ratio of 28.96, a PEG ratio of 2.42 and a beta of 0.77. The business has a 50 day moving average of $95.87 and a two-hundred day moving average of $91.48. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $106.33. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the business posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.